One of the leading global contract manufacturing organisations, Aesica Pharmaceuticals, has announced a key addition to its corporate quality team as it continues to expand.
Edd Wood has been promoted from his role as Regulatory Affairs Manager to Director of Corporate Quality. Edd has worked with Aesica and has been based at its Cramlington site since the company’s inception in 2004. Prior to this he worked in quality assurance and quality control at BASF and at Procter & Gamble.
More recently he played a key role at Aesica in establishing its manufacturing presence in Europe and ensuring consistent, stringent quality protocols were implemented at the sites the company acquired in 2011. Edd’s experience was harnessed to enhance the company’s wider approach to quality control and assurance and his new role will be instrumental in shaping quality and validation protocols in the future.
Speaking about his promotion, Edd said: “Having worked for Aesica for over eight years and having been involved in the company’s recent expansion into Europe, I am well placed to develop and strengthen the company’s current quality protocols. The challenge for any CMO in relation to quality assurance and control is that our clients, both large pharma organisation and emerging companies, are assured of our stringent adherence to quality procedures and that while our manufacturing services offer increased value, quality remains at the heart of our operations.
“As we continue to grow as an organisation, so too will the pressures to maintain the high standards of quality we currently deliver to the marketplace. However, our audit approval history is exemplary and it is my responsibility to build upon this proven track record and further enhance our procedures as we move forward.“
Edd will provide corporate support to the manufacturing operations team at Aesica and oversee the continuous implementation of new and enhanced quality measures across all existing and potential new sites at Aesica.
Chris Gowland, Corporate Manufacturing & Compliance Director, Aesica Pharmaceuticals, said: “I am delighted to announce Edd’s appointment into this new senior role. He has played a pivotal role in the quality and compliance team since joining Aesica and I am confident that Edd will continue to support the evolution of the business as we expand further globally. Quality is a vital aspect of the contract manufacturing process and our record in this arena is excellent. Edd will ensure that the highest possible standards are maintained and that our processes are enhanced continually for the benefit of all of our customers.”
Currently four out of six Aesica manufacturing sites – Cramlington and Queenborough in the UK; Monheim and Zwickau in Germany – hold FDA approval and the company is committed to ensuring all of its sites comply to the highest possible operational standards.